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Abstract - In diabetes, pancreatic islets are subjected to high levels of inflammatory mediators that can lead to beta cell 
destruction. We recently showed that pancreatic islet cells derived from MIF-deficient (MIF-KO) mice are resistant to 
apoptosis induction by the cytotoxic stimuli of cytokines. Here we show that MIF-KO islets under cytokine (IFN-γ+TNF-
α+IL-1β) stimulation express and secrete significantly lower amounts of IL-1β, while the expression of caspase-1 mRNA 
is not influenced by MIF deficiency. These data suggest that MIF-KO islets possess an innate defect in the process of IL-1 
β synthesis and secretion.
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INTRODUCTION
Diabetes mellitus refers to a group of chronic dis-
eases, where Type 1 diabetes (T1D) and Type 2 dia-
betes (T2D) constitute its two main forms (Brooks-
Worrell and Palmer, 2011). In T1D, damage to the 
beta cells occurs via T lymphocyte and macrophage 
infiltration of the islets of Langerhans and exposure 
to the proinflammatory mediators that these cells 
produce, such as cytokines (TNF-α, IL-1β, IL-17, 
IL-18, IFN-γ, MIF) and reactive oxygen and nitro-
gen species (Cnop et al., 2005; Eizirik et al., 2009). 
Moreover, the beta cells themselves contribute to the 
production of some of the cytokines, chemokines 
and nitric oxide under a proinflammatory stimulus 
(Kaminitz et al., 2007). In T2D, slow progressive 
low-grade inflammatory processes take place, and 
the beta cells succumb to a predominantly mito-
chondria-dependent apoptosis associated with the 
increase in circulating proinflammatory cytokines 
and free fatty acids or glucose (Stumvoll et al., 2005; 
Masters et al., 2010). Thus, although the instigating 
factors that lead to beta cell destruction in T1D and 
T2D are distinct, both forms of diabetes present an 
inflammatory pathogenesis in which the beta cells 
perish (reviewed in Donath et al., 2008). Moreover, 
IL-1β seems to be a common mediator involved in 
beta cell destruction in both types of diabetes (Din-
arello et al., 2010).
Macrophage migration inhibitory factor (MIF) 
is a proinflammatory cytokine of the innate immune 
system that plays a major role in the onset and devel-
opment of several inflammation-based diseases, in-
cluding diabetes (reviewed in: Cvetković and Stošić-
Grujičić, 2006; Stošić-Grujičić et al., 2009; Stojanović 
et al., 2012). One of the main characteristics of MIF 
is its ability to recruit cells of both innate and ac-
quired immunity to the site of inflammation and to 
amplify the production of various proinflammatory 
mediators such as TNF-α, IL-1β, IFN-γ, IL-17, nitric 
oxide (Calandra and Bucala, 1997), thus positioning 
MIF at the top of the inflammatory cascade. The final 
stage of this cascade is the activation of pro-apoptot-
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ic signals that may lead to beta cell death. Indeed, we 
have demonstrated that neutralization, or deletion of 
MIF prevents beta cell death in diabetes in mice by 
the modulation of cytokines shown to be relevant to 
disease pathogenesis (Cvetković et al., 2005; Stošić-
Grujičić et al., 2008). Our in vitro studies further sup-
ported the role of MIF in the functional suppression 
and propagation of insulin-producing pancreatic is-
let cell death (Stojanović et al., 2008; Saksida et al., 
2011). Interestingly, this protein with extraordinar-
ily versatile functions was found to be present within 
the insulin secretory granules in the beta cells, and to 
act as an autocrine factor to stimulate insulin release 
(Waeber et al., 1997). However, beside this function, 
one can postulate that MIF could influence the final 
stage of the cytokine-mediated apoptotic cascade. 
On the other hand, diabetes, as an IL-1β-mediated 
disease, is often termed ‘‘auto-inflammatory’’ and the 
dominant finding is the release of the active form of 
IL-1β. This led us to examine the possible involve-
ment of MIF in the local control of this important 
proinflammatory and cytotoxic mediator. In order to 
study the causal relationship between MIF and IL-1β 
within the target tissue, we compared the expression 
of IL-1β between the pancreatic islets obtained from 
wild type C57BL/6 mice and that of genetically defi-
cient MIF-KO mice. We demonstrated that the ab-
sence of MIF affected the production of IL-1β, which 
could be one more explanation for the previously ob-




Unless otherwise stated, all chemicals were pur-
chased from Sigma-Aldrich, St Louis, MO, USA.
Isolation of pancreatic islets and treatments
The experiments were approved by the Ethics Com-
mittee for Animal Experimentation at the Belgrade 
University and conducted in accordance with local 
and international legislation regarding the wellbeing 
of laboratory animals. Pancreatic islets were prepared 
from homozygous mif gene-deficient (MIF-KO) mice 
(Fingerle-Rowson et al., 2003), as well as from their 
age-matched wild-type (WT) C57BL/6 counterparts. 
The islets were isolated using a collagenase V diges-
tion technique, followed by handpicking (Rydgren 
and Sandler, 2002). Before performing the experi-
ments, the islets were cultured overnight in RPMI-
1640 medium containing 10% FCS (PAA Chemicals, 
Pasching, Austria), 10 mM HEPES, 5 μM 2-mercap-
toethanol, 2 mM L-glutamine, 1 mM sodium pyru-
vate, 100 IU/ml penicillin and 100 µg/ml streptomy-
cin in a humidified (5% CO2, 95% air) atmosphere 
at 37°C in 6-well non-adhesive culture plates, or in 
96-well tissue culture plates, as will be indicated in 
the Results. The pancreatic islets were treated with a 
mixture of murine cytokines IFN-γ+TNF-α+IL-1β 
(R&D, Minneapolis, MN, USA), 10 ng/ml each.
RNA isolation, reverse transcription and PCR
Total RNA was isolated from the pancreatic islets 
(groups of 80) with TRIzol reagent (Genosys, Wood-
lands, TX) according to the manufacturer’s instruc-
tions. RNA was reverse-transcribed using Moloney 
leukemia virus reverse transcriptase and random 
hexamers (Pharmacia, Uppsala, Sweden). PCR am-
plification of cDNA with primers specific for the 
gene in question and β-actin as a housekeeping gene 
was carried out in a Mastercycler Gradient thermal 
cycler (Eppendorf, Hamburg, Germany) as follows: 
30 s of denaturation at 95°C, 30 s of annealing at 
58°C, and 30 s of extension at 72°C. For each gene, 
preliminary experiments were conducted to ascer-
tain that amplification of the cDNA was in the lin-
ear range under the respective cycling conditions. 
Primer pair sequences are given in Table 1. The PCR 
products were visualized by electrophoresis in 2.5% 
agarose gels containing ethidium bromide; the gels 
were photographed by GelDoc (Biorad, Hercules, 
CA, USA) and the results were analyzed by densit-
ometry using Kodak 1D 3.6 software.
Determination of IL-1β levels in culture media
IL-1β concentrations in the supernatants of cultured 
pancreatic islets were measured by sandwich ELISA 
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according to the manufacturer’s instructions. The 
paired IL-1β antibodies specific for mouse IL-1β 
were from R&D. The results were calculated using a 
standard curve, constructed using known concentra-
tions of recombinant mouse IL-1β (R&D).
Statistical analysis
The results from at least 3 experiments were present-
ed as means ± SD. Differences were assessed using 
the unpaired Student’s t-test. A P value less than 0.05 
was taken to be statistically significant. The statistical 
package used was Statistica 7.0 (StatSoft Inc., Tulsa, 
OK, USA).  
RESULTS
IL-1β is produced by the beta cells in an inflamma-
tory milieu and operates in a paracrine and autocrine 
fashion to induce apoptosis in beta cells (Kaminitz et 
al., 2007; Pirot et al., 2008). To determine the caus-
al relationship between MIF and IL-1β generation 
within a pancreatic islet, we used the pancreatic islets 
isolated from MIF-KO and C57BL/6 mice (WT). To 
mimic an inflammatory insult, the islets were treat-
ed with a cytokine cocktail (TNF-α+IL-1β+IFN-γ). 
After 6 h of incubation, we investigated the expres-
sion of IL-1β mRNA in untreated islets and their cy-
tokine-stimulated counterparts. While basal expres-
sion of IL-1β mRNA was similar in WT and MIF-KO 
islet cells, upon exposure to the cytotoxic cytokine 
insult the MIF-KO islets expressed lower levels of IL-
1β mRNA compared to the WT islets (Fig. 1a). 
We then examined the secretion of IL-1β upon 
cytokine stimulation, as well as basal secretion of the 
protein. In order to prevent interference with IL-1β 
detection, we used rat recombinant IL-1β for stimu-
lation, while for detection by ELISA, antibody pairs 
specific for mouse IL-1β were used. After 24 h of cul-
tivation, a significant amount of IL-1β was detected 
in the culture supernatants of both MIF-KO and WT 
islets. However, upon exposure to the cytokine cock-
tail, the secretion of the formed protein was almost 
completely suppressed in the MIF-KO islets (Fig. 
1b), while it was upregulated in the WT islets. 
As caspase-1 is necessary for the activation of IL-
1β, we explored its expression and found that cas-
pase-1 mRNA is not constitutively expressed in the 
islets of Langerhans of both mouse strains (Fig. 2). 
In addition, after cytokine treatment the stimulation 
Fig. 1. MIF absence affects IL-1β generation. Pancreatic islets 
from C57BL/6 or MIF-KO mice were incubated in the pres-
ence or absence of a cytokine mixture (IL-1β+IFN-γ+TNF-α- 
10 ng/ml each) for determination of IL-1β mRNA expression 
(in groups of 100) by PCR after 6 h (a), and IL-1β secretion (in 
groups of 20) by ELISA after 24 h (b). Data are presented as the 
mean ± SD; * indicates P<0.05 cytokine-treated vs. untreated (0), 
while # indicates P<0.05 MIF-KO vs. C57BL/6 islets. Photos of 
PCR amplicons were displayed above the corresponding graphs; 
lower lane – β-actin, upper line – gene in question.
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of caspase-1 mRNA expression was similar in both 
MIF-deficient and MIF-producing islets (Fig. 2). 
DISCUSSION
In diabetes, uncontrolled inflammation may cause 
cellular dysfunction and aggravate tissue damage. 
There is evidence that cytokines exist in ‘‘cascades’’ 
and that interrupting just one cytokine can interrupt 
the whole cascade (Dinarello, 2010). We previously 
reported that the absence of MIF could rescue beta 
cells from the damaging effects of a cytokine-rich 
milieu (Stojanović et al., 2008; Stojanović et al., 2012 
and Stojanović et al., in press). In the current study, 
we demonstrated that the absence of MIF downregu-
lates cytokine-induced IL-1β expression and secre-
tion within pancreatic islets. Since IL-1β is the most 
potent beta cell cytotoxic cytokine, our results sug-
gest a dominant role for MIF in the final step of the 
inflammatory cascade within the target tissue, which 
may lead to beta cell dysfunction and destruction in 
a setting of localized inflammation.
IL-1β under physiologic circumstances plays 
an important role in the daily maintenance of beta 
cell mass and function (Maedler et al., 2006). How-
ever, the long-term and pathologically elevated lev-
els of islet IL-1β associated with inflammation of 
the islet lead to decreased beta cell function and 
mass (Donath et al., 2010). Therefore, IL-1β is one 
of the principal cytokines implicated in both T1D 
and T2D (Mandrup-Poulsen et al., 1986; Dinarello 
et al., 2010). A key feature of these two diseases is 
the failure to control the processing and secretion 
of IL-1β. On the other hand, MIF is known to acti-
vate downstream proinflammatory cytokines such as 
IL-1β, TNF-α, and IL-17, IFN-γ (Flaster et al., 2007; 
Stojanović et al., 2009). Interestingly, both MIF and 
IL-1β are produced by the beta cells themselves (Wae-
ber et al., 1997; Heitmeier et al., 2001). In the present 
study, we found that MIF is the cytokine that directly 
regulates IL-1β generation within the islet cells. Al-
though IL-1β mRNA expression was upregulated in 
the cytokine-stimulated MIF-KO islets, it was much 
lower in comparison to MIF sufficient counterparts. 
Moreover, the secretion of IL-1β was suppressed in 
the presence of cytokines, suggesting a block in pro-
tein synthesis, activation of IL-1β, or a defect in the 
secretory mechanism. From this, one may conclude 
that MIF is the cytokine that mediates a significant 
loss in beta-cell function and/or mass. 
IL-1β activity is tightly controlled and requires 
the conversion of the primary transcript, the inac-
tive IL-1β precursor, to the active cytokine by lim-
ited proteolysis. This can take place extracellularly 
by serine proteases, or intracellularly by the IL-1-
converting enzyme, also known as caspase-1 (Din-
arello, 2011). When caspase-1 is activated, the IL-
1β precursor is cleaved and secretion takes place. 
Therefore, the rate-limiting step in the processing 
and release of active IL-1β may be at the level of 
this enzyme. However, in contrast to IL-1β mRNA 
expression, we found that caspase-1 expression was 
fully preserved in stimulated MIF-KO islets, suggest-
ing that the actions of TNF-α and IFN-γ were suf-
Fig. 2. MIF absence does not affect caspase-1 mRNA expression. 
Pancreatic islets from C57BL/6 or MIF-KO mice were incubated 
in the presence or absence of cytokine mixture (IL-1β+IFN-
γ+TNF-α- 10 ng/ml each) for determination of caspase-1 mRNA 
expression (in groups of 100) by PCR after 6 h of incubation. 
Data are presented as the mean ± SD; * indicates P<0.05 cy-
tokine-treated vs. untreated (0). Photos of PCR amplicons were 
displayed above the adequate graphs; lower lane – β-actin, upper 
line – gene in question.
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ficient for enzyme induction. IL-1β itself increases 
the synthesis of caspase-1 as well as its own IL-1β 
precursor (Karlsen et al., 2000). A similar case may 
exist for the beta cell (Maedler et al., 2002), although 
IL-1-induced caspase-1 expression has not yet been 
demonstrable in the pancreatic islet. Since caspase-1 
was fully expressed in the MIF-KO islets, it could 
be assumed that activation of IL-1β was operative. 
However, elevated levels of caspase-1 mRNA does 
not necessarily imply the presence of the active en-
zyme product necessary for IL-1β maturation, since 
activation of caspase-1 is tightly controlled by a mo-
lecular complex, the inflammasome (Agostini et al., 
2004). Indeed, in the pancreas, the intracellular ac-
cumulation of ROS due to hyperglycemia activates 
the NLRP3 inflammasome and promotes the release 
of IL-1β from beta cells (Masters et al., 2010). Nev-
ertheless, the rate-limiting steps in the secretion of 
IL-1β of MIF-KO islet cells might be at the transcrip-
tional and translational levels, as well as at the level 
of secretion itself.
CONCLUSION
The inability of the IL-1β, TNF-α and IFN-γ cocktail 
to sufficiently activate IL-1β expression and secretion 
in MIF-KO islet cells proves a dominant and indis-
pensable role of MIF as a key factor of IL-1 genera-
tion in the pancreas. These data suggest that MIF-KO 
islets possess an innate defect in the process of IL-1β 
synthesis or secretion. Reducing IL-1β activity may 
hold promise for correcting dysfunctional beta-cell 
production of insulin in diabetes, including a possi-
bility that the suppression of IL-1β-mediated inflam-
mation in the microenvironment of the islet allows 
their regeneration.
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